Genius Biotherapeutics (Genius)
(Bioclones (Pty) Ltd)
Established in 1982, Genius is arguably the oldest health care biotechnology company in South Africa, if not the African continent, with a track record of investing in research and development work that led to successfully commercialising South Africa’s first biosimilar product, Repotin, a recombinant human hormone known as Erythropoietin (EPO).
Genius focuses on health care applications and more specifically on the production of biopharmaceutical products. Biopharmaceutical products include such therapeutics as hormones, protein-based drugs and antibodies.
Genius is a research and development biopharmaceutical group of companies which includes the following operational business units:
- Immunotherapy dendritic cell vaccine (DCV) technology
- EPO production, registered as Repotin
- Granulocyte-colony stimulating factor (G-CSF) product development
- Integrated Bioworks (IBW) reagents